In a landscape where pharmacological interventions often dominate the treatment of chronic insomnia, a new clinical development from Vivos Therapeutics Inc. is shifting the focus toward non-invasive, mechanical solutions. Recent unpublished clinical data indicates that the company’s Vida oral appliance—a device previously utilized for temporomandibular joint (TMJ) disorders—has yielded significant success in mitigating insomnia severity, potentially offering a transformative path for patients suffering from comorbid insomnia and sleep apnea (COMISA).
The Core Data: A Breakthrough in Insomnia Management
The study, conducted at a single clinical site between 2022 and 2025, focused on 37 adult participants—30 women and 7 men—ranging in age from 28 to 77. All participants suffered from longstanding, clinically moderate-to-severe insomnia. By utilizing the Insomnia Severity Index (ISI), a gold-standard validated metric for assessing sleep disruption, researchers tracked the efficacy of the Vida appliance over an average usage period of 3.7 months.
The findings were striking: participants saw an average reduction in ISI scores of approximately 65%. Most notably, the study reported a 100% success rate in terms of symptom improvement, with every single participant advancing by at least one full ISI classification level. By the conclusion of the study, no patient remained in the “moderate to severe” category, with all participants categorized as having either “no clinically significant insomnia” or “subthreshold insomnia.”
Chronology of the Clinical Investigation
To understand the trajectory of this development, one must look at the timeline of the Vida appliance’s evolution.
- Pre-2023: The device, then known as the "Pod" oral appliance, was developed by Advanced Facialdontics, primarily designed to assist in the management of bruxism (teeth grinding) and TMD.
- Early 2023: Vivos Therapeutics acquired the technology, integrating it into their suite of sleep and airway management products.
- 2022–2025: Dr. Scott Simonetti, the inventor of the Unilateral BiteBlock Technology utilized within the Vida appliance, spearheaded the clinical study. Throughout this three-year window, the cohort of 37 patients provided the longitudinal data necessary to evaluate the device’s impact on insomnia rather than just jaw-related symptoms.
- Post-2025: Following the analysis of the data, Vivos has begun positioning the device as a potential new modality for the broader insomnia market, pending further dissemination of the clinical findings.
Understanding the Technology: How Vida Works
The Vida appliance is not a traditional sleep aid. Unlike sedative-hypnotic medications that influence neurochemical pathways to induce sleep, the Vida appliance functions as a mechanical intervention. At its core is the Unilateral BiteBlock Technology, designed to modulate the autonomic nervous system during sleep.
Dr. Scott Simonetti, reflecting on the study’s success, suggests that the device’s efficacy lies in its ability to balance the nervous system, which is often hyper-aroused in patients with chronic insomnia. By stabilizing the jaw and, by extension, the airway and facial musculature, the device appears to create a physiological environment conducive to restorative sleep. While the device currently holds FDA Class II clearance specifically for the amelioration of clenching and bruxing associated with TMD, the implications of these new findings suggest that the mechanism of action may extend far beyond the jaw joint.
Official Responses and Strategic Vision
R. Kirk Huntsman, Chairman and CEO of Vivos Therapeutics, views these results as a validation of the company’s long-term strategy to address the complex intersection of sleep disorders.
"The results of this clinical study are consistent with what we’ve seen with thousands of COMISA patients—symptomatic relief comes fast, with no material safety issues, and appears to have lasting effects—all at a reasonable cost," Huntsman stated in a press release. He emphasized that the findings offer a dual advantage for the company: providing a high-impact solution for one of the world’s most pervasive and costly health conditions, while simultaneously opening a significant new revenue stream.
The financial model associated with this treatment is distinctive. Vivos estimates that it can realize approximately $2,000 per patient through a combination of diagnostic testing and the provision of the device. However, a hurdle remains: while home EEG testing may qualify for insurance reimbursement, the Vida appliance itself is currently not widely covered by insurance carriers, placing the burden of cost on the patient.
The Context of COMISA: A Growing Public Health Concern
The clinical data arrives at a time when medical professionals are increasingly recognizing the prevalence of COMISA—Comorbid Insomnia and Obstructive Sleep Apnea. Research suggests that as many as 60% of patients diagnosed with moderate to severe obstructive sleep apnea also struggle with chronic insomnia.
Historically, treating these conditions in tandem has been difficult. Continuous Positive Airway Pressure (CPAP) therapy, while effective for apnea, can sometimes exacerbate insomnia symptoms due to the physical discomfort of the mask or the noise of the machine. The Vida appliance offers an alternative that is non-pharmacological and, according to early reports, highly tolerable for patients who have failed to find relief through traditional means.
Implications for Future Clinical Adoption
While the study is limited by its single-site nature and the relatively small sample size of 37 patients, the 100% improvement rate is a figure that demands further investigation. Vivos has stated that it has been advised that the current data is sufficient to proceed without additional FDA clearance for the specific claim of insomnia treatment, though the company will likely look toward larger, multi-site trials to solidify its market position.
For clinicians, the appeal of the Vida appliance lies in its “nonpharmacologic” nature. As the medical community moves away from heavy reliance on sleep medications—which carry risks of dependency and side effects like next-day grogginess—the shift toward structural and neurological modulation is gaining traction.
Dr. Simonetti remains optimistic about the road ahead. "I believe the Vida helps modulate autonomic nervous system balance during sleep, and the consistency of improvement across all 37 patients in the study suggests real potential for broader clinical adoption as awareness and supporting data continue to emerge," he noted.
Regulatory and Financial Considerations
The path forward for Vivos involves navigating the intersection of clinical evidence and consumer accessibility. The fact that the Vida appliance is already FDA-cleared for TMD provides a regulatory "foot in the door." By repurposing an existing device for a new clinical indication, Vivos may be able to bypass the lengthy and costly de novo approval process that would be required for an entirely new medical device.
However, the "out-of-pocket" nature of the device payment remains a significant factor in patient adoption. For the Vida appliance to become a standard of care for insomnia, Vivos will likely need to leverage this new data to lobby for more robust insurance reimbursement codes, or alternatively, demonstrate such clear clinical superiority that patients are willing to prioritize the expenditure as an essential health investment.
Conclusion: A New Era for Insomnia Patients?
The study on the Vida appliance serves as a compelling reminder that the most effective solutions for sleep disorders are often those that work in harmony with the body’s natural architecture. By addressing the physical components of sleep disruption, Vivos Therapeutics has opened a new chapter in the treatment of insomnia.
While the data is currently classified as unpublished and remains to be vetted by the broader scientific community through peer-reviewed journals, the preliminary success of the 37-patient cohort is significant. As awareness of COMISA grows and the demand for drug-free sleep solutions rises, the Vida appliance stands as a promising candidate for those who have exhausted traditional options. Whether this device becomes a cornerstone of insomnia treatment will depend on the scalability of these results and the company’s ability to communicate the value of this technology to both the clinical community and the patients who need it most.
As the medical field continues to refine its understanding of the relationship between airway health, jaw alignment, and sleep architecture, the Vida appliance may prove to be a landmark innovation in the quest for a better night’s sleep.
